FGP
PFE icon

Freestone Grove Partners’s Pfizer PFE Stock Holding History

Freestone Grove Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.27M Sell
80,886
-968,995
-92% -$25.8M 0.02% 363
2025
Q4 		$26.1M Buy
+1,049,881
New +$26.5M 0.19% 174
2025
Q2 		– Sell
-31,287
Closed -$793K – 812
2025
Q1 		$793K Buy
31,287
+13,153
+73% +$344K 0.01% 364
2024
Q4 		$481K Buy
+18,134
New +$492K 0.01% 382

Other funds holding PFE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Freestone Grove Partners's PFE Position: Q1 2026 in Review

Freestone Grove Partners reduced its Pfizer (PFE) stake by 92% in Q1 2026, selling an estimated $25.8M and leaving 80,886 shares worth $2.27M. The position accounts for 0.02% of the portfolio, ranked #363.

Freestone Grove Partners first reported a position in PFE in Q4 2024 and has held it in 4 quarters since. The position peaked at $26.1M in Q4 2025. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Freestone Grove Partners held 80,886 shares of Pfizer worth $2.27M as of Q1 2026.
  • Freestone Grove Partners sold 968,995 Pfizer shares in Q1 2026, an estimated $25.8M.
  • Pfizer made up 0.02% of Freestone Grove Partners's portfolio in Q1 2026, its #363 holding.
  • Freestone Grove Partners first reported a position in Pfizer in Q4 2024 and has held it in 4 quarters since.
  • Freestone Grove Partners's Pfizer position peaked at $26.1M in Q4 2025.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.